{
  "claim_id": "claim_001",
  "claim": "Flublok contains 3x the hemagglutinin (HA) antigen content of standard-dose flu vaccines, which has been linked to greater immunogenicity vs standard-dose flu vaccines.",
  "document": "Liu_et_al.__2024_",
  "additional_evidence_check": {
    "checked_for_more": true,
    "found_additional": true,
    "additional_count": 3
  },
  "completeness_stats": {
    "existing_evidence": 3,
    "new_evidence_found": 3,
    "total_evidence": 4
  },
  "combined_evidence": [
    {
      "id": 1,
      "quote": "a cell culture based influenza vaccine (Flucelvax Quadrivalent by Seqirus, Inc., ccIIV4) and a recombinant influenza vaccine (Flublok Quadrivalent by Sanofi Pasteur, RIV4). RIV4 contains 3 times the intended 45 \u00b5g HA/dose/strain compared to IIV4 and ccIIV4 (15 \u00b5g HA/dose/strain).",
      "relevance_explanation": "This quote explicitly states that Flublok (RIV4) contains 3 times the hemagglutinin (HA) antigen content per strain compared to standard-dose flu vaccines (IIV4 and ccIIV4), directly supporting the first part of the claim."
    },
    {
      "id": 2,
      "quote": "For A (H3N2), RIV4 vaccination not only improved the quality of the functional neutralizing antibody response compared to IIV4 and ccIIV4, it also significantly increased the quantity of the total A (H3N2) cell HA head binding antibodies (Fig. 4A, Fig. S1A).",
      "relevance_explanation": "This quote provides direct evidence that the higher HA content in Flublok (RIV4) is linked to greater immunogenicity, as measured by both the quality and quantity of antibody responses, compared to standard-dose vaccines."
    },
    {
      "id": 3,
      "quote": "In year 1, RIV4 induced higher neutralizing and total HA head binding antibodies to cell-A (H3N2) virus than ccIIV4 and IIV4.",
      "relevance_explanation": "This quote shows that RIV4 (Flublok) led to higher antibody responses than standard-dose vaccines, supporting the claim that increased HA content is associated with greater immunogenicity."
    },
    {
      "id": "comp_1",
      "quote": "In this randomized trial (Clinical trials gov: NCT03722589), sera pre- and post vaccination with quadrivalent inactivated egg based (IIV4), cell culture based (ccIIV4), and recombinant (RIV4) influenza vaccines were compared. RIV4 contains 3 times the intended 45 \u00b5g HA/dose/strain compared to IIV4 and ccIIV4 (15 \u00b5g HA/dose/strain).",
      "relevance_explanation": "This quote explicitly states that RIV4 (Flublok) contains three times the hemagglutinin (HA) antigen content per strain compared to standard-dose flu vaccines (IIV4 and ccIIV4), directly supporting the first part of the claim.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    }
  ],
  "completeness_assessment": {
    "missing_aspects": []
  },
  "model_used": "gpt-4.1"
}